Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Lymphoid 3Other hematologic neoplasm 2Sarcoma 1Genitourinary 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × plitidepsin × Plasma cell × Clear all
NCT03117361 2020-12-02

Trial of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

PharmaMar

Phase 2 Terminated
10 enrolled 37 charts
Plasma cell

Multiple Myeloma

NCT01102426 2020-11-10

ADMYRE

PharmaMar

Phase 3 Completed
255 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT02100657 2020-10-12

Study of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

PharmaMar

Phase 1 Completed
39 enrolled 30 charts
Plasma cell

Multiple Myeloma

NCT00229203 2009-12-24

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

PharmaMar

Phase 2 Completed
51 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔